AnaptysBio Q2 net loss $46.7M; cash $393.5M; ANB032 Phase 2b enrollment complete, data Dec 2024

ANAPTYSBIO, INC

2024-Q2 EPS reported -$3.35 revenue$18,150,000

Net loss of $46.7M ($1.71 per share) for Q2 2024, vs $39.8M loss ($1.50) in Q2 2023.
Cash & investments $393.5M as of June 30, 2024; runway reiterated through year-end 2026.
Completed enrollment (~200 patients) for ANB032 Phase 2b in atopic dermatitis; top-line data expected Dec 2024.
Rosnilimab Phase 2b RA top-line data accelerated to Q1 2025; Phase 2 UC data now expected Q1 2026.
IND for ANB033 (anti-CD122) accepted by FDA; Phase 1 trial initiation anticipated in Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.